Tag: Skin and soft tissue infections

According to the Infectious Diseases Society of America (IDSA), both trimethoprim-sulfamethoxazole (Bactrim) and doxycycline are recommended options for treating mild to moderate community-acquired MRSA (CA-MRSA) skin and soft-tissue infections. The question of which is better for MRSA, Bactrim or Doxycycline, hinges on the specific infection, local resistance patterns, patient history, and potential side effects.

Tigecycline, a first-in-class glycylcycline antibiotic, was developed to combat the rising threat of multidrug-resistant (MDR) pathogens. Approved in 2005, it is a crucial intravenous treatment reserved for serious infections when other antibiotics are ineffective or unsuitable.